Copper‐Catalyzed Remote C(sp
<sup>3</sup>
)−H Trifluoromethylation of Carboxamides and Sulfonamides
作者:Zhonglin Liu、Haiwen Xiao、Benxiang Zhang、Haigen Shen、Lin Zhu、Chaozhong Li
DOI:10.1002/anie.201813425
日期:2019.2.18
catalyst, the reaction of N‐fluoro‐substituted carboxamides (or sulfonamides) with Zn(CF3)2 complexes provides the corresponding δ‐trifluoromethylated carboxamides (or sulfonamides) in satisfactory yields under mild reaction conditions. A radical mechanism involving 1,5‐hydrogen atom transfer of N‐radicals followed by CF3‐transfer from CuII−CF3 complexes to the thus formed alkyl radicals is proposed.
本文报道的是未活化的脂族C(sp 3)-H键的三氟甲基化的空前协议。以Cu(OTf)2为催化剂,N-氟取代的羧酰胺(或磺酰胺)与Zn(CF 3)2配合物的反应在温和的反应条件下以令人满意的收率提供了相应的δ-三氟甲基化的羧酰胺(或磺酰胺)。提出了一种自由基机理,涉及N自由基的1,5-氢原子转移,然后从Cu II -CF 3络合物向如此形成的烷基自由基进行CF 3-转移。
Practical Synthesis of Phthalimides and Benzamides by a Multicomponent Reaction Involving Arynes, Isocyanides, and CO<sub>2</sub>/H<sub>2</sub>O
作者:Trinadh Kaicharla、Manikandan Thangaraj、Akkattu T. Biju
DOI:10.1021/ol500403x
日期:2014.3.21
Transition-metal-freemulticomponentreactionsinvolvingarynes and isocyanides with either CO2 or H2O have been reported. With CO2 as the third component, the reactions resulted in the formation of N-substituted phthalimides. The utility of water as the third component furnished benzamide derivatives in moderate to good yields. These reactions took place under mild conditions with broad scope.
Hydroxy substituted amides for the treatment of alzheimer's disease
申请人:Beck P. James
公开号:US20050038019A1
公开(公告)日:2005-02-17
The present invention is a method of treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of known compounds of Formula (I), wherein, A, R, J, and n are as defined herein.
Phenyl Compounds and Their Use in the Treatment of Type II Diabetes
申请人:Blaszczak Larry Chris
公开号:US20080221217A1
公开(公告)日:2008-09-11
The present invention is directed to compounds of formula (I) or a pharmaceutically acceptable salt thereof; wherein A is (xx); X is selected from CH, CF and N, R5 is selected from H, C
1
-C
6
alkyl, C
1
-C
6
fluoroalkyl, and —OR12, R9 is selected from H and —C(O)NR1OR11, R12 is selected from H, C
1
-C
6
alkyl and C
3
-C
6
cycloalkyl for use as inhibitors of the DPP-IV enzyme in the treatment or prevention of conditions including Type II diabetes.
Phenyl compounds and their use in the treatment of Type II diabetes
申请人:Eli Lilly and Company
公开号:US08076514B2
公开(公告)日:2011-12-13
The present invention is directed to compounds of formula (I) or a pharmaceutically acceptable salt thereof; wherein A is (xx); X is selected from CH, CF and N, R5 is selected from H, C1-C6 alkyl, C1-C6 fluoroalkyl, and —OR12, R9 is selected from H and —C(O)NR1OR1 1, R12 is selected from H, C1-C6 alkyl and C3-C6 cycloalkyl for use as inhibitors of the DPP-IV enzyme in the treatment or prevention of conditions including Type II diabetes.